Merck FDA Approval of IDVYNSO HIV Treatment Drug

Rahway, New Jersey, USA – April 21, 2026

In a major breakthrough for HIV therapeutics, Merck has received U.S. FDA approval for IDVYNSO™ (doravirine/islatravir), a once-daily, two-drug regimen designed for adults living with virologically suppressed HIV-1 infection. This approval marks a significant innovation in antiretroviral therapy, introducing the first non-INSTI, tenofovir-free complete regimen that has demonstrated non-inferior efficacy compared to standard three-drug treatments, offering patients a simplified yet effective alternative.

Innovative Two-Drug Regimen Redefining HIV Care

The newly approved IDVYNSO combines doravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), with islatravir, a next-generation nucleoside reverse transcriptase inhibitor (NRTI) with multiple mechanisms of action, including translocation inhibition and viral DNA disruption. This dual-action approach enables effective viral suppression with fewer drugs, representing a paradigm shift in HIV management.

Unlike traditional regimens that often include integrase inhibitors (INSTIs) and tenofovir, IDVYNSO offers a diverse therapeutic option, particularly valuable for patients requiring treatment switching due to tolerability, comorbidities, or drug interactions. The therapy is intended for individuals who are already virologically suppressed (HIV-1 RNA <50 copies/mL) and have no history of treatment failure or resistance to doravirine, ensuring optimal clinical outcomes.

This once-daily single-tablet regimen also addresses the growing need for simplified HIV treatment, especially in aging populations managing multiple chronic conditions.

Strong Phase 3 Data Supporting Approval

The FDA approval is supported by robust data from two Phase 3 randomized clinical trials involving over 700 participants. These studies demonstrated that IDVYNSO achieved non-inferior efficacy compared to standard antiretroviral therapies, including the widely used three-drug regimen BIKTARVY.

In one key trial, 92% of patients switching to IDVYNSO maintained viral suppression at 48 weeks, closely matching outcomes seen with comparator therapies. In another study, 96% of patients maintained suppression, outperforming baseline regimens in certain groups. Importantly, only 1% of patients experienced virologic failure, highlighting the regimen’s high efficacy and durability.

The safety profile was found to be comparable to existing therapies, with low discontinuation rates and commonly reported adverse events including mild gastrointestinal symptoms, dizziness, and fatigue. Minimal weight changes were observed, further supporting its favorable tolerability profile.

These findings reinforce IDVYNSO’s role as a clinically validated, effective alternative for long-term HIV management.

Expanding Treatment Options and Future Outlook

The approval of IDVYNSO reflects Merck’s continued commitment to advancing HIV research and treatment innovation, building on decades of scientific progress in antiviral therapies. As the global HIV population ages, there is increasing demand for treatment regimens that balance efficacy, safety, and convenience, and IDVYNSO is positioned to meet these evolving needs.

Importantly, the therapy introduces greater flexibility in treatment selection, allowing clinicians to tailor regimens based on individual patient profiles, including comorbid conditions and long-term medication burden. However, careful consideration of drug interactions and contraindications, such as co-administration with strong CYP3A inducers, remains essential to ensure optimal outcomes.

With availability expected in pharmacies shortly after approval, IDVYNSO is poised to reshape the HIV treatment landscape, offering a simplified, effective, and well-tolerated option for millions of patients worldwide.

This milestone underscores the broader trend toward precision and patient-centric HIV care, where innovative drug combinations continue to enhance both clinical outcomes and quality of life for people living with HIV.

Source: Merck press release